Left Ventricular Ejection Fraction clinical trials at UCSF
2 in progress, 0 open to eligible people
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
Sorry, not currently recruiting here
The purpose of this study is to assess the efficacy and safety of the study drug, levosimendan (given orally), compared to placebo in participants with pulmonary hypertension with heart failure with preserved left ventricular ejection fraction (PH-HFpEF) as measured by the change in 6-Minute Walk Distance.
San Francisco, California and other locations
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
Sorry, in progress, not accepting new patients
This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).
San Francisco, California and other locations
Last updated: